Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03026504 · ClinicalTrials.gov registry record · Phase 2
Baricitinib in Relapsing Giant Cell Arteritis
A Phase 2 study of Arteritis, Giant Cell, sponsored by Matthew J Koster.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT03026504: Completed Phase 2 study of Arteritis, Giant Cell, sponsored by Matthew J Koster.
NCT03026504 is a Phase 2 study of Arteritis, Giant Cell that has completed, run by Matthew J Koster. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03026504, a Phase 2 study of Arteritis, Giant Cell, has completed, sponsored by Matthew J Koster.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety and effectiveness of baricitinib in the treatment of giant cell arteritis. All participants will be taking prednisone at the start of the study. The prednisone will be reduced according to a standardized tapering schedule while participants continue to take one tablet of baricitinib daily for 52 weeks.
Primary Outcome
The percentage of subjects who experienced greater than or equal to one adverse event
Conditions Studied
Interventions
- DRUG Baricitinib
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-03-09 |
| Est. Completion | 2021-04-12 |
| Phase | Phase 2 |
What the finished NCT03026504 record still lists
NCT03026504 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Arteritis, Giant Cell appearing as the primary indexed condition, and to 1 intervention - of which Baricitinib is the first listed.
NCT03026504 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03026504 about?
NCT03026504 is a clinical study titled "Baricitinib in Relapsing Giant Cell Arteritis". This study will evaluate the safety and effectiveness of baricitinib in the treatment of giant cell arteritis. All participants will be taking prednisone at the start of the study. The prednisone will be reduced according to a standardized tapering schedule while participants continue to take one ta...
What is the current status of trial NCT03026504?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2017-03-09. Estimated completion is 2021-04-12.
What conditions does trial NCT03026504 study?
This clinical trial studies the following conditions: Arteritis, Giant Cell.
What interventions are being tested in trial NCT03026504?
The interventions under investigation include: Baricitinib (DRUG).
Who is sponsoring clinical trial NCT03026504?
This trial is sponsored by Matthew J Koster, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03026504 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03026504's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI